Sanofi Reassures Investors About Diabetes Franchise, Says Late-Stage Pipeline Will Reduce Lantus Dependence

Sanofi used a keenly awaited investor day to extoll its late-stage pipeline and voice optimism about its key diabetes franchise, but avoided mention of the “elephant in the room” – the pharma’s lack of a CEO after last month’s dramatic expulsion of Chris Viehbacher.